Title
Category
Credits
Event date
Cost
  • Disease management
  • 0.75 ACPE - Pharmacists
  • 0.75 ACPE - Pharmacy Technicians
  • 0.75 ADA - CERP (Dentists/Allied Dental Staff)
  • 0.75 AMA - Physicians
  • 0.75 ANCC - Nurses
  • 0.75 APA - Psychologists
  • 0.75 Attendance - General Attendance
  • 0.75 CDR - Dietitians
  • 0.75 ASWB - Social Workers
$0.00
This activity will focus on enhancing our understanding of the current opioid crisis and will explore new angles and address current concerns, including the use of over-the-counter intranasal naloxone, the evolving landscape of opioids with a focus on fentanyl, the intersection between suicide and opioid overdoses, the significance of the new 988 helpline in the crisis, and the viability of home-based detox startups. Strategies to effectively address the ongoing challenges of the opioid crisis will be discussed.
  • Disease management
  • Oncology
  • 1.00 ACPE - Pharmacists
  • 1.00 ACPE - Pharmacy Technicians
  • 1.00 ADA - CERP (Dentists/Allied Dental Staff)
  • 1.00 AMA - Physicians
  • 1.00 ANCC - Nurses
  • 1.00 APA - Psychologists
  • 1.00 Attendance - General Attendance
  • 1.00 CDR - Dietitians
  • 1.00 ASWB - Social Workers
$0.00
This activity aims to explore best practices in cancer screening and shed light on the groundbreaking WISDOM Study, which is revolutionizing our approach to screening by testing a personalized precision-medicine method based on individual risk factors for breast cancer in contrast to traditional annual mammograms. Participants will learn how this alternative approach differs from the current “one-size-fits-all” guideline-based method and discuss its potential to significantly improve the effectiveness of screening.
  • Disease management
  • 1.00 ACPE - Pharmacists
  • 1.00 ACPE - Pharmacy Technicians
  • 1.00 ADA - CERP (Dentists/Allied Dental Staff)
  • 1.00 AMA - Physicians
  • 1.00 ANCC - Nurses
  • 1.00 APA - Psychologists
  • 1.00 Attendance - General Attendance
  • 1.00 CDR - Dietitians
  • 1.00 ASWB - Social Workers
$0.00
Alzheimer’s disease (AD) is a pressing public health crisis, affecting more than 6 million people in the U.S. and increasing in prevalence with the aging population. Join us in exploring the latest advances in AD diagnosis and management, including biomarkers, imaging techniques and cognitive assessments. Emerging pharmacological therapies that target the underlying disease and novel approaches to optimizing patient care will be highlighted.

Pages